Portage Biotech Inc - Asset Resilience Ratio
Portage Biotech Inc (PRTG) has an Asset Resilience Ratio of 0.00% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2021)
This chart shows how Portage Biotech Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Portage Biotech Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Portage Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Portage Biotech Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Portage Biotech Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Portage Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Portage Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Portage Biotech Inc (2000–2021)
The table below shows the annual Asset Resilience Ratio data for Portage Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-03-31 | 0.00% | $0.00 | $174.86 Million | -- |
| 2020-03-31 | 0.04% | $68.00K | $173.17 Million | -0.02pp |
| 2019-03-31 | 0.06% | $103.00K | $173.72 Million | -0.46pp |
| 2018-03-31 | 0.52% | $52.00K | $10.00 Million | -97.83pp |
| 2017-03-31 | 98.35% | $58.91 Million | $59.90 Million | +95.31pp |
| 2012-03-31 | 3.04% | $228.12K | $7.51 Million | -17.29pp |
| 2011-03-31 | 20.32% | $1.96 Million | $9.62 Million | +7.27pp |
| 2010-03-31 | 13.05% | $1.33 Million | $10.22 Million | -55.48pp |
| 2009-03-31 | 68.52% | $864.47K | $1.26 Million | -0.83pp |
| 2008-03-31 | 69.36% | $3.53 Million | $5.09 Million | +19.67pp |
| 2007-03-31 | 49.69% | $2.87 Million | $5.78 Million | +17.07pp |
| 2006-03-31 | 32.62% | $1.53 Million | $4.68 Million | +31.11pp |
| 2005-03-31 | 1.51% | $63.15K | $4.20 Million | -25.91pp |
| 2000-03-31 | 27.42% | $480.04K | $1.75 Million | -- |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more